Free Trial
→ Trump’s treachery (From Porter & Company) (Ad) Buy NBIX Stock  Free NBIX Stock Alerts

Neurocrine Biosciences (NBIX) Financials

Neurocrine Biosciences logo
$124.72 +1.69 (+1.37%)
As of 10:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Neurocrine Biosciences

Annual Income Statements for Neurocrine Biosciences

This table shows Neurocrine Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 341 250 155 90 407 37 21 -143 -141 -89
Consolidated Net Income / (Loss)		 341 250 155 90 407 37 21 -143 -141 -89
Net Income / (Loss) Continuing Operations		 341 250 155 90 407 37 21 -143 -141 -89
Total Pre-Tax Income 		486 332 214 101 107 47 22 -143 -141 -89
Total Operating Income		 571 251 249 103 163 72 37 -131 -147 -94
Total Gross Profit		 2,321 1,847 1,466 1,119 1,036 781 446 160 15 20
Total Revenue		 2,355 1,887 1,489 1,134 1,046 788 451 162 15 20
Operating Revenue		 2,355 1,887 1,489 1,134 1,046 788 451 162 15 20
Total Cost of Revenue		 34 40 23 14 10 7.40 4.90 1.25 0.00 0.00
Operating Cost of Revenue		 34 40 23 14 10 7.40 4.90 1.25 0.00 0.00
Total Operating Expenses		 1,751 1,597 1,217 1,017 873 708 410 292 162 114
Selling, General & Admin Expense		 1,007 888 753 583 433 354 249 170 68 32
Research & Development Expense		 744 709 464 433 440 354 161 122 94 81
Total Other Income / (Expense), net		 -85 81 -35 -1.10 -56 -26 -15 -11 6.28 5.27
Interest Expense		 138 0.00 70 26 51 32 31 20 0.00 0.00
Interest & Investment Income		 91 53 4.10 3.80 13 19 16 8.34 6.28 1.93
Other Income / (Expense), net		 -37 28 31 21 -18 -13 0.00 0.00 - 3.35
Income Tax Expense		 145 82 59 12 -301 9.50 0.70 - 0.00 -
Basic Earnings per Share		 $3.40 $2.56 $1.61 $0.95 $4.38 $0.40 $0.23 ($1.62) ($1.63) ($1.05)
Weighted Average Basic Shares Outstanding		 100.40M 97.70M 95.80M 94.60M 93.10M 91.60M 90.20M 88.09M 86.71M 84.50M
Diluted Earnings per Share		 $3.29 $2.47 $1.56 $0.92 $4.16 $0.39 $0.22 ($1.62) ($1.63) ($1.05)
Weighted Average Diluted Shares Outstanding		 103.70M 101M 98.90M 97.90M 97.80M 95.70M 95.40M 88.09M 86.71M 84.50M
Weighted Average Basic & Diluted Shares Outstanding		 99.70M 99.51M 96.59M 95.24M 93.94M 92.50M 91.80M 88M 86.60M 84.70M

Quarterly Income Statements for Neurocrine Biosciences

This table shows Neurocrine Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 7.90 103 130 65 43 148 83 96 -77 89 69
Consolidated Net Income / (Loss)		 7.90 103 130 65 43 148 83 96 -77 89 69
Net Income / (Loss) Continuing Operations		 7.90 103 130 65 43 148 83 96 -77 89 69
Total Pre-Tax Income 		15 163 190 99 35 198 116 122 -103 118 98
Total Operating Income		 24 142 184 145 99 150 141 74 -114 103 88
Total Gross Profit		 563 618 614 581 508 507 488 441 412 404 382
Total Revenue		 573 628 622 590 515 515 499 453 420 412 388
Operating Revenue		 573 628 622 590 515 515 499 453 420 412 388
Total Cost of Revenue		 9.20 9.30 8.00 9.20 7.50 8.50 11 12 8.50 7.70 6.10
Operating Cost of Revenue		 9.20 9.30 8.00 9.20 7.50 8.50 11 12 8.50 7.70 6.10
Total Operating Expenses		 540 476 430 436 409 356 346 368 526 301 294
Selling, General & Admin Expense		 277 288 234 242 243 219 204 222 243 183 186
Research & Development Expense		 263 189 196 194 165 138 142 146 283 118 108
Total Other Income / (Expense), net		 -8.90 21 6.50 -47 -65 48 -26 48 11 15 10
Interest Expense		 0.00 88 0.00 50 1.10 -1.10 0.00 0.00 1.10 -6.00 1.20
Interest & Investment Income		 22 21 23 23 23 18 15 11 9.80 1.30 0.20
Other Income / (Expense), net		 -31 87 -17 -20 -87 29 -40 37 2.20 7.20 11
Income Tax Expense		 6.80 60 61 34 -8.90 51 33 26 -27 29 29
Basic Earnings per Share		 $0.08 $1.05 $1.28 $0.64 $0.43 $1.52 $0.85 $0.98 ($0.79) $0.92 $0.72
Weighted Average Basic Shares Outstanding		 99.70M 100.40M 101.10M 100.80M 99.80M 97.70M 97.90M 97.60M 97.10M 95.80M 95.80M
Diluted Earnings per Share		 $0.08 $1.00 $1.24 $0.63 $0.42 $1.49 $0.82 $0.95 ($0.79) $0.91 $0.69
Weighted Average Diluted Shares Outstanding		 102.50M 103.70M 104.30M 103.90M 103.60M 101M 101.10M 100.20M 97.10M 98.90M 99M
Weighted Average Basic & Diluted Shares Outstanding		 98.97M 99.70M 101.25M 100.98M 100.64M 99.51M 98.25M 97.65M 97.57M 96.59M 96.13M

Annual Cash Flow Statements for Neurocrine Biosciences

This table details how cash moves in and out of Neurocrine Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 -18 -12 -73 154 75 -32 -112 171 9.16 43
Net Cash From Operating Activities		 595 390 339 257 229 147 101 -94 -106 -38
Net Cash From Continuing Operating Activities		 595 390 339 257 229 147 101 -94 -106 -38
Net Income / (Loss) Continuing Operations		 341 250 155 90 407 37 21 -143 -141 -89
Consolidated Net Income / (Loss)		 341 250 155 90 407 37 21 -143 -141 -89
Depreciation Expense		 24 18 15 11 8.60 7.40 4.00 2.40 1.45 1.01
Amortization Expense		 -23 -15 4.20 25 21 20 19 14 3.52 6.03
Non-Cash Adjustments To Reconcile Net Income		 371 166 212 113 136 88 58 43 24 25
Changes in Operating Assets and Liabilities, net		 -118 -29 -47 18 -345 -6.00 -0.70 -10 5.49 19
Net Cash From Investing Activities		 -127 -467 -177 -130 4.10 -211 -243 -251 113 -196
Net Cash From Continuing Investing Activities		 -127 -467 -177 -130 4.10 -211 -243 -251 113 -196
Purchase of Property, Plant & Equipment		 -38 -28 -17 -23 -11 -15 -25 -6.94 -4.11 -1.93
Acquisitions		 0.00 0.00 -43 0.00 0.00 - - - - -
Purchase of Investments		 -1,056 -1,411 -629 -805 -736 -866 -546 -583 -299 -449
Sale and/or Maturity of Investments		 968 972 511 698 751 670 328 339 416 255
Net Cash From Financing Activities		 -487 65 -234 27 -158 32 30 517 2.39 277
Net Cash From Continuing Financing Activities		 -487 65 -234 27 -158 32 30 517 2.39 277
Repayment of Debt		 -309 0.00 -279 -0.10 -187 0.00 0.00 - - -
Repurchase of Common Equity		 -300 0.00 0.00 - - - - - - -
Issuance of Common Equity		 122 65 45 28 29 32 30 14 2.39 277
Effect of Exchange Rate Changes		 0.00 0.30 -1.30 0.00 0.00 - - - - -
Cash Interest Paid		 1.60 3.80 6.60 8.60 12 12 12 6.24 0.00 0.00
Cash Income Taxes Paid		 218 52 14 5.10 15 0.50 0.00 0.00 - 0.00

Quarterly Cash Flow Statements for Neurocrine Biosciences

This table details how cash moves in and out of Neurocrine Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -39 -116 209 -257 145 -43 134 57 -159 51 49
Net Cash From Operating Activities		 65 243 158 65 130 124 212 180 -125 143 99
Net Cash From Continuing Operating Activities		 65 243 158 65 130 124 212 180 -125 143 99
Net Income / (Loss) Continuing Operations		 7.90 103 130 65 43 148 83 96 -77 89 69
Consolidated Net Income / (Loss)		 7.90 103 130 65 43 148 83 96 -77 89 69
Depreciation Expense		 6.60 6.20 5.60 6.40 5.30 4.90 4.60 4.20 4.10 3.90 4.00
Amortization Expense		 -3.60 -4.70 -5.60 -6.10 -6.20 -5.50 -5.10 -3.00 -1.20 3.20 0.20
Non-Cash Adjustments To Reconcile Net Income		 83 54 58 127 132 9.10 88 31 38 36 32
Changes in Operating Assets and Liabilities, net		 -30 84 -30 -127 -44 -33 42 52 -89 11 -5.90
Net Cash From Investing Activities		 14 -68 25 -28 -55 -202 -97 -126 -42 -116 -61
Net Cash From Continuing Investing Activities		 14 -68 25 -28 -55 -202 -97 -126 -42 -116 -61
Purchase of Property, Plant & Equipment		 -11 -7.30 -8.10 -12 -11 -5.40 -7.60 -6.80 -8.50 -1.80 1.70
Purchase of Investments		 -273 -312 -233 -192 -320 -487 -363 -324 -238 -233 -134
Sale and/or Maturity of Investments		 298 251 265 175 276 291 273 205 204 162 71
Net Cash From Financing Activities		 -118 -290 26 -293 70 35 19 2.90 8.20 25 11
Net Cash From Continuing Financing Activities		 -118 -290 26 -293 70 35 19 2.90 8.20 25 11
Repurchase of Common Equity		 -150 - - - - - - - - - -
Issuance of Common Equity		 32 10 26 16 70 35 19 2.90 8.20 25 11
Cash Income Taxes Paid		 0.60 73 52 93 0.20 47 1.60 3.20 0.20 10 1.20

Annual Balance Sheets for Neurocrine Biosciences

This table presents Neurocrine Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 3,719 3,251 2,369 2,073 1,735 1,306 993 818 365 475
Total Current Assets		 1,725 1,607 1,454 973 1,016 831 738 555 310 384
Cash & Equivalents		 233 251 263 341 187 112 142 255 83 74
Short-Term Investments		 843 781 726 371 614 558 509 261 224 305
Accounts Receivable		 479 439 350 186 157 127 57 31 0.00 -
Inventories, net		 57 38 35 31 28 17 11 1.02 - -
Other Current Assets		 112 98 79 46 30 17 19 6.84 3.09 4.88
Plant, Property, & Equipment, net		 83 71 59 59 45 42 34 11 6.27 3.43
Total Noncurrent Assets		 1,911 1,574 857 1,041 674 433 222 252 48 87
Long-Term Investments		 864 849 299 624 265 356 216 247 43 82
Intangible Assets		 37 36 37 0.00 - - - - - -
Noncurrent Deferred & Refundable Income Taxes		 486 363 306 315 319 0.00 - - - -
Other Noncurrent Operating Assets		 525 326 214 102 89 74 - - - -
Total Liabilities & Shareholders' Equity		 3,719 3,251 2,369 2,073 1,735 1,306 993 818 365 475
Total Liabilities		 1,129 1,019 661 699 609 669 512 445 50 50
Total Current Liabilities		 508 655 538 246 187 565 88 54 30 26
Short-Term Debt		 0.00 170 169 0.00 - 409 - - - -
Accounts Payable		 462 449 348 226 169 141 86 54 26 2.56
Other Current Liabilities		 46 36 21 20 18 15 1.86 0.91 0.24 0.43
Total Noncurrent Liabilities		 621 365 123 453 422 104 424 391 20 25
Other Noncurrent Operating Liabilities		 621 365 123 118 104 104 36 8.04 8.10 13
Total Equity & Noncontrolling Interests		 2,590 2,232 1,708 1,374 1,126 637 481 372 315 424
Total Preferred & Common Equity		 2,590 2,232 1,708 1,374 1,126 637 481 372 315 424
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2,590 2,232 1,708 1,374 1,126 637 481 372 315 424
Common Stock		 2,555 2,382 2,123 2,012 1,850 1,768 1,660 1,573 1,372 1,341
Retained Earnings		 29 -157 -407 -636 -725 -1,133 -1,178 -1,199 -1,056 -915
Accumulated Other Comprehensive Income / (Loss)		 5.80 7.00 -7.90 -1.70 1.80 1.40 -1.93 -1.85 -0.32 -0.98

Quarterly Balance Sheets for Neurocrine Biosciences

This table presents Neurocrine Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 3,688 3,535 3,305 3,472 2,848 2,613 2,360 2,143
Total Current Assets		 1,638 1,877 1,670 1,799 1,650 1,497 1,433 1,206
Cash & Equivalents		 194 349 140 396 294 160 104 212
Short-Term Investments		 749 879 899 814 801 817 791 587
Accounts Receivable		 516 481 468 451 418 388 392 301
Inventories, net		 59 46 43 37 29 32 33 37
Other Current Assets		 119 122 120 101 108 101 113 68
Plant, Property, & Equipment, net		 87 80 80 75 69 66 63 61
Total Noncurrent Assets		 1,963 1,578 1,555 1,598 1,130 1,051 864 877
Long-Term Investments		 910 771 638 864 455 343 245 363
Intangible Assets		 36 35 34 34 35 37 37 -
Noncurrent Deferred & Refundable Income Taxes		 499 454 420 378 383 379 337 319
Other Noncurrent Operating Assets		 518 319 464 322 257 292 245 195
Total Liabilities & Shareholders' Equity		 3,688 3,535 3,305 3,472 2,848 2,613 2,360 2,143
Total Liabilities		 1,152 816 796 1,086 846 760 675 599
Total Current Liabilities		 523 430 399 713 692 583 374 485
Accounts Payable		 475 393 359 417 503 392 356 298
Other Current Liabilities		 48 37 40 173 19 21 18 18
Total Noncurrent Liabilities		 629 386 397 373 155 178 301 114
Other Noncurrent Operating Liabilities		 629 386 397 373 155 178 132 114
Total Equity & Noncontrolling Interests		 2,536 2,719 2,509 2,386 2,002 1,853 1,685 1,545
Total Preferred & Common Equity		 2,536 2,719 2,509 2,386 2,002 1,853 1,685 1,545
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2,536 2,719 2,509 2,386 2,002 1,853 1,685 1,545
Common Stock		 2,532 2,623 2,555 2,497 2,309 2,242 2,171 2,054
Retained Earnings		 -5.30 81 -49 -114 -305 -388 -483 -496
Accumulated Other Comprehensive Income / (Loss)		 9.00 15 2.50 3.30 -1.70 -1.10 -2.70 -14

Annual Metrics And Ratios for Neurocrine Biosciences

This table displays calculated financial ratios and metrics derived from Neurocrine Biosciences' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 24.81% 26.76% 31.34% 8.38% 32.71% 74.67% 179.16% 977.51% -24.12% 0.00%
EBITDA Growth		 89.27% -5.62% 88.11% -9.30% 101.49% 45.73% 151.72% 18.95% -69.89% -48.21%
EBIT Growth		 90.98% -0.18% 126.74% -15.07% 145.03% 61.14% 128.01% 10.86% -62.20% -48.53%
NOPAT Growth		 112.38% 4.89% 98.57% -85.44% 981.56% 61.52% 138.74% 10.86% -56.44% -46.25%
Net Income Growth		 36.68% 61.62% 72.43% -78.00% 1,000.81% 75.36% 114.80% -1.03% -58.65% -46.89%
EPS Growth		 33.20% 58.33% 69.57% -77.88% 966.67% 77.27% 113.58% 0.61% -55.24% -29.63%
Operating Cash Flow Growth		 52.71% 14.88% 32.32% 12.25% 55.44% 44.97% 207.49% 11.16% -179.45% 19.40%
Free Cash Flow Firm Growth		 6.40% 826.43% -137.11% -63.59% 586.85% 198.02% 111.93% -2.33% -103.14% -8.29%
Invested Capital Growth		 24.60% -11.45% 57.61% -1.16% 2,203.66% 619.48% 87.87% 36.26% 2.78% -53.16%
Revenue Q/Q Growth		 5.02% 5.79% 7.20% 5.99% 0.36% 16.68% 8.92% 140.84% 0.00% 0.00%
EBITDA Q/Q Growth		 10.53% 26.88% 58.84% -29.58% 20.23% 48.75% 5.71% 35.32% -16.43% -12.84%
EBIT Q/Q Growth		 10.23% 32.62% 73.47% -37.55% 25.26% 78.08% 13.24% 30.66% -14.73% -12.73%
NOPAT Q/Q Growth		 -6.44% 21.91% 132.41% -84.83% 392.97% 27.06% 32.62% 30.66% -11.76% -12.25%
Net Income Q/Q Growth		 -11.56% 30.73% 165.46% -79.86% 336.08% 75.63% 112.55% 26.56% -12.20% -12.49%
EPS Q/Q Growth		 -12.96% 30.69% 168.97% -79.87% 320.20% 0.00% 0.00% 27.35% -10.88% -11.70%
Operating Cash Flow Q/Q Growth		 24.98% -4.76% 69.19% -26.04% -1.30% 47.01% 10.84% 43.36% -18.30% 0.28%
Free Cash Flow Firm Q/Q Growth		 -17.47% 203.58% 68.70% -67.42% 118.33% 4,542.06% 49.76% 31.48% -12.78% -4.19%
Invested Capital Q/Q Growth		 -9.86% -16.25% 6.65% 3.21% 571.05% -66.90% -162.11% -96.23% -11.97% -14.55%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 98.56% 97.90% 98.44% 98.74% 99.03% 99.06% 98.91% 99.22% 100.00% 100.00%
EBITDA Margin		 22.69% 14.96% 20.09% 14.03% 16.76% 11.04% 13.23% -71.41% -949.33% -423.98%
Operating Margin		 24.22% 13.30% 16.73% 9.04% 15.58% 9.17% 8.16% -81.27% -982.48% -476.51%
EBIT Margin		 22.65% 14.80% 18.79% 10.89% 13.89% 7.52% 8.16% -81.27% -982.48% -459.59%
Profit (Net Income) Margin		 14.49% 13.23% 10.38% 7.90% 38.94% 4.69% 4.68% -88.19% -940.60% -449.84%
Tax Burden Percent		 70.23% 75.19% 72.23% 88.36% 381.72% 79.57% 96.79% 100.00% 100.00% 100.00%
Interest Burden Percent		 91.11% 118.90% 76.45% 82.17% 73.43% 78.41% 59.24% 108.51% 95.74% 97.88%
Effective Tax Rate		 29.77% 24.81% 27.77% 11.64% -281.72% 20.43% 3.21% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 68.46% 34.00% 37.40% 24.11% 315.68% 868.82% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 71.71% 29.69% 39.79% 24.23% 347.08% 872.54% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -54.31% -21.33% -27.37% -16.95% -269.48% -862.20% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 14.16% 12.68% 10.03% 7.17% 46.20% 6.62% 4.95% -41.50% -38.17% -28.09%
Cash Return on Invested Capital (CROIC)		 46.56% 46.15% -7.33% 25.29% 132.32% 231.54% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 15.31% 9.94% 12.60% 6.48% 9.56% 5.16% 4.06% -22.21% -35.09% -25.31%
Return on Assets (ROA)		 9.79% 8.89% 6.96% 4.71% 26.79% 3.22% 2.33% -24.11% -33.60% -24.78%
Return on Common Equity (ROCE)		 14.16% 12.68% 10.03% 7.17% 46.20% 6.62% 4.95% -41.50% -38.17% -28.09%
Return on Equity Simple (ROE_SIMPLE)		 13.18% 11.19% 9.05% 6.52% 36.17% 5.81% 4.39% -38.30% -44.81% -20.95%
Net Operating Profit after Tax (NOPAT)		 401 189 180 91 622 58 36 -92 -103 -66
NOPAT Margin		 17.01% 10.00% 12.08% 7.99% 59.49% 7.30% 7.89% -56.89% -687.74% -333.56%
Net Nonoperating Expense Percent (NNEP)		 -3.25% 4.31% -2.39% -0.11% -31.40% -3.72% -3.29% -13.42% -9.23% -6.54%
Return On Investment Capital (ROIC_SIMPLE)		 15.47% 7.85% 9.58% - - - - - - -
Cost of Revenue to Revenue		 1.44% 2.10% 1.56% 1.26% 0.97% 0.94% 1.09% 0.78% 0.00% 0.00%
SG&A Expenses to Revenue		 42.76% 47.04% 50.56% 51.46% 41.43% 44.93% 55.16% 105.12% 453.87% 164.30%
R&D to Revenue		 31.57% 37.57% 31.15% 38.24% 42.02% 44.96% 35.59% 75.38% 628.61% 412.22%
Operating Expenses to Revenue		 74.33% 84.60% 81.72% 89.70% 83.45% 89.89% 90.76% 180.50% 1,082.48% 576.51%
Earnings before Interest and Taxes (EBIT)		 533 279 280 123 145 59 37 -131 -147 -91
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 534 282 299 159 175 87 60 -115 -142 -84
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 5.34 5.80 6.72 5.88 7.95 15.54 13.47 18.45 10.68 11.49
Price to Tangible Book Value (P/TBV)		 5.41 5.89 6.87 5.88 7.95 15.54 13.47 18.45 10.68 11.49
Price to Revenue (P/Rev)		 5.87 6.86 7.71 7.13 8.56 12.56 14.35 42.48 224.13 246.66
Price to Earnings (P/E)		 40.49 51.84 74.32 90.18 21.99 267.54 306.90 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 2.47% 1.93% 1.35% 1.11% 4.55% 0.37% 0.33% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 18.30 21.56 17.61 18.96 21.72 565.97 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 5.04 5.95 6.96 6.25 7.85 11.78 13.29 40.05 200.74 223.30
Enterprise Value to EBITDA (EV/EBITDA)		 22.23 39.80 34.65 44.52 46.82 106.69 100.46 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 22.27 40.22 37.04 57.37 56.48 156.52 162.97 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 29.65 59.55 57.62 78.16 13.19 161.34 168.37 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 19.95 28.81 30.53 27.60 35.92 63.14 59.14 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 43.61 43.88 0.00 74.54 31.47 244.44 470.69 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.08 0.10 0.24 0.28 0.64 0.81 0.99 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.24 0.28 0.00 0.81 0.99 0.00 0.00
Financial Leverage		 -0.76 -0.72 -0.69 -0.70 -0.78 -0.99 -1.03 -1.10 -1.11 -1.11
Leverage Ratio		 1.45 1.43 1.44 1.52 1.72 2.06 2.12 1.72 1.14 1.13
Compound Leverage Factor		 1.32 1.70 1.10 1.25 1.27 1.61 1.26 1.87 1.09 1.11
Debt to Total Capital		 0.00% 7.08% 9.02% 19.61% 22.01% 39.09% 44.69% 49.83% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 7.08% 9.02% 0.00% 0.00% 39.09% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 19.61% 22.01% 0.00% 44.69% 49.83% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 92.92% 90.98% 80.39% 77.99% 60.91% 55.31% 50.17% 100.00% 100.00%
Debt to EBITDA		 0.00 0.60 0.57 2.11 1.81 4.70 6.51 -3.20 0.00 0.00
Net Debt to EBITDA		 0.00 -6.06 -3.74 -6.29 -4.27 -7.10 -8.01 3.41 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 2.11 1.81 0.00 6.51 -3.20 0.00 0.00
Debt to NOPAT		 0.00 0.90 0.94 3.70 0.51 7.11 10.91 -4.02 0.00 0.00
Net Debt to NOPAT		 0.00 -9.07 -6.22 -11.05 -1.20 -10.73 -13.43 4.28 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 3.70 0.51 0.00 10.91 -4.02 0.00 0.00
Altman Z-Score		 8.86 8.77 11.67 7.68 9.70 8.66 7.28 7.60 35.75 55.75
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.40 2.45 2.70 3.96 5.45 1.47 8.36 10.20 10.21 14.94
Quick Ratio		 3.06 2.25 2.49 3.65 5.14 1.41 8.03 10.05 10.11 14.75
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 272 256 -35 95 261 38 13 -107 -104 -51
Operating Cash Flow to CapEx		 1,558.64% 1,377.74% 2,056.97% 1,096.15% 2,096.33% 1,000.00% 408.87% -1,360.61% -2,592.94% -1,973.87%
Free Cash Flow to Firm to Interest Expense		 1.97 0.00 -0.50 3.68 5.09 1.19 0.42 -5.47 0.00 0.00
Operating Cash Flow to Interest Expense		 4.30 0.00 4.85 9.94 4.46 4.59 3.32 -4.83 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 4.03 0.00 4.61 9.03 4.25 4.13 2.51 -5.19 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.68 0.67 0.67 0.60 0.69 0.69 0.50 0.27 0.04 0.06
Accounts Receivable Turnover		 5.13 4.78 5.56 6.62 7.37 8.57 10.19 0.00 0.00 0.00
Inventory Turnover		 0.71 1.08 0.71 0.49 0.45 0.53 0.82 0.00 0.00 0.00
Fixed Asset Turnover		 30.71 29.17 25.40 21.97 24.18 20.80 20.20 18.92 3.09 6.66
Accounts Payable Turnover		 0.07 0.10 0.08 0.07 0.07 0.07 0.07 0.03 0.00 0.00
Days Sales Outstanding (DSO)		 71.16 76.33 65.65 55.16 49.50 42.61 35.81 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 513.68 337.42 516.03 746.59 818.54 694.59 442.77 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 4,886.71 3,661.03 4,510.58 5,034.70 5,601.49 5,615.01 5,210.45 11,599.37 0.00 0.00
Cash Conversion Cycle (CCC)		 -4,301.86 -3,247.28 -3,928.90 -4,232.95 -4,733.44 -4,877.81 -4,731.87 -11,599.37 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 649 521 589 373 378 16 -3.16 -26 -41 -42
Invested Capital Turnover		 4.02 3.40 3.10 3.02 5.31 119.02 -30.91 -4.83 -0.36 -0.57
Increase / (Decrease) in Invested Capital		 128 -67 215 -4.40 361 20 23 15 1.17 -15
Enterprise Value (EV)		 11,880 11,235 10,363 7,079 8,207 9,282 5,997 6,473 3,011 4,414
Market Capitalization		 13,820 12,946 11,482 8,080 8,955 9,899 6,476 6,866 3,362 4,876
Book Value per Share		 $25.58 $22.72 $17.76 $14.48 $12.05 $6.92 $5.30 $4.21 $3.62 $4.92
Tangible Book Value per Share		 $25.22 $22.36 $17.38 $14.48 $12.05 $6.92 $5.30 $4.21 $3.62 $4.92
Total Capital		 2,590 2,402 1,877 1,709 1,444 1,046 869 742 315 424
Total Debt		 0.00 170 169 335 318 409 388 370 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 335 318 0.00 388 370 0.00 0.00
Net Debt		 -1,940 -1,711 -1,119 -1,001 -748 -617 -478 -394 -351 -462
Capital Expenditures (CapEx)		 38 28 17 23 11 15 25 6.93 4.10 1.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 141 91 96 16 29 4.00 -1.37 -15 -27 -21
Debt-free Net Working Capital (DFNWC)		 1,217 1,122 1,085 727 830 675 650 500 280 358
Net Working Capital (NWC)		 1,217 952 916 727 830 266 650 500 280 358
Net Nonoperating Expense (NNE)		 59 -61 25 0.97 215 21 15 51 38 23
Net Nonoperating Obligations (NNO)		 -1,940 -1,711 -1,119 -1,001 -748 -621 -484 -398 -356 -466
Total Depreciation and Amortization (D&A)		 0.90 3.00 19 36 30 28 23 16 4.97 7.04
Debt-free, Cash-free Net Working Capital to Revenue		 5.98% 4.81% 6.44% 1.39% 2.74% 0.51% -0.30% -9.55% -182.15% -105.38%
Debt-free Net Working Capital to Revenue		 51.67% 59.47% 72.90% 64.14% 79.33% 85.59% 143.96% 309.66% 1,866.85% 1,812.73%
Net Working Capital to Revenue		 51.67% 50.46% 61.52% 64.14% 79.33% 33.71% 143.96% 309.66% 1,866.85% 1,812.73%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $3.40 $2.56 $1.61 $0.95 $4.38 $0.40 $0.23 ($1.62) ($1.63) ($1.05)
Adjusted Weighted Average Basic Shares Outstanding		 100.40M 97.70M 95.80M 94.60M 93.10M 91.63M 90.24M 88.09M 86.71M 84.50M
Adjusted Diluted Earnings per Share		 $3.29 $2.47 $1.56 $0.92 $4.16 $0.39 $0.22 ($1.62) ($1.63) ($1.05)
Adjusted Weighted Average Diluted Shares Outstanding		 103.70M 101M 98.90M 97.90M 97.80M 95.73M 95.39M 88.09M 86.71M 84.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.40 $0.23 ($1.62) $0.00 ($1.05)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 99.70M 99.51M 96.59M 95.24M 93.94M 92.29M 90.82M 89.27M 87.11M 86.45M
Normalized Net Operating Profit after Tax (NOPAT)		 401 189 180 91 114 58 36 -92 -103 -66
Normalized NOPAT Margin		 17.01% 10.00% 12.08% 7.99% 10.91% 7.30% 7.89% -56.89% -687.74% -333.56%
Pre Tax Income Margin		 20.63% 17.60% 14.37% 8.95% 10.20% 5.90% 4.83% -88.19% -940.60% -449.84%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 3.85 0.00 4.00 4.78 2.84 1.85 1.21 -6.73 0.00 0.00
NOPAT to Interest Expense		 2.89 0.00 2.57 3.51 12.15 1.80 1.17 -4.71 0.00 0.00
EBIT Less CapEx to Interest Expense		 3.58 0.00 3.76 3.88 2.63 1.39 0.39 -7.08 0.00 0.00
NOPAT Less CapEx to Interest Expense		 2.62 0.00 2.33 2.60 11.94 1.34 0.35 -5.07 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 87.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Neurocrine Biosciences

This table displays calculated financial ratios and metrics derived from Neurocrine Biosciences' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 11.12% 21.84% 24.72% 30.37% 22.57% 25.05% 28.59% 19.70% 35.35% 32.05% 31.05%
EBITDA Growth		 -104.00% 28.88% 65.90% 12.22% 110.36% 51.83% -2.42% 117.25% -508.61% 1,605.80% 137.01%
EBIT Growth		 -106.94% 27.61% 65.08% 13.17% 110.89% 62.12% 2.22% 134.46% -586.96% 1,500.00% 172.45%
NOPAT Growth		 -89.85% -19.61% 23.51% 65.83% 256.26% 43.50% 65.22% 50.96% -4,070.10% 407.18% 87.14%
Net Income Growth		 -81.80% -30.20% 56.20% -31.94% 156.66% 65.96% 21.31% 665.09% -651.08% 1,319.18% 204.44%
EPS Growth		 -80.95% -32.89% 51.22% -33.68% 153.16% 63.74% 18.84% 627.78% -664.29% 1,400.00% 200.00%
Operating Cash Flow Growth		 -50.27% 96.36% -25.47% -64.03% 204.07% -13.64% 114.57% 30.05% -209.14% 3,304.76% 59.87%
Free Cash Flow Firm Growth		 -158.13% -121.27% -12.33% 68.84% 274.83% 230.91% 124.19% 31.91% -16.69% -552.29% 52.85%
Invested Capital Growth		 57.16% 24.60% 15.77% 18.35% -39.23% -11.45% 12.76% 30.53% 26.99% 57.61% 52.52%
Revenue Q/Q Growth		 -8.78% 0.90% 5.40% 14.54% 0.02% 3.29% 10.18% 7.68% 2.04% 6.21% 2.56%
EBITDA Q/Q Growth		 -101.74% 37.99% 32.67% 1,013.27% -93.23% 77.63% -10.26% 202.75% -191.76% 14.16% 99.81%
EBIT Q/Q Growth		 -103.06% 37.09% 32.99% 928.69% -93.20% 77.35% -8.84% 199.02% -201.27% 11.83% 109.09%
NOPAT Q/Q Growth		 -85.91% -28.18% 30.79% -23.27% 11.53% 10.35% 75.60% 172.31% -202.42% 27.06% 60.44%
Net Income Q/Q Growth		 -92.34% -20.57% 99.69% 49.77% -70.62% 77.74% -12.98% 224.67% -186.07% 29.93% 505.33%
EPS Q/Q Growth		 -92.00% -19.35% 96.83% 50.00% -71.81% 81.71% -13.68% 220.25% -186.81% 31.88% 483.33%
Operating Cash Flow Q/Q Growth		 -73.28% 53.48% 144.58% -50.42% 5.51% -41.75% 18.04% 243.45% -187.55% 44.74% -28.46%
Free Cash Flow Firm Q/Q Growth		 -517.41% -239.96% 182.01% -108.20% 125.92% 476.81% 129.15% 53.98% -69.17% -6.59% 17.96%
Invested Capital Q/Q Growth		 5.14% -9.86% -13.48% 91.64% -16.64% -16.25% -11.54% -1.59% 21.46% 6.65% 2.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 98.39% 98.52% 98.71% 98.44% 98.54% 98.35% 97.75% 97.46% 97.98% 98.13% 98.43%
EBITDA Margin		 -0.70% 36.69% 26.83% 21.31% 2.19% 34.69% 20.17% 24.76% -25.95% 28.57% 26.58%
Operating Margin		 4.12% 22.62% 29.55% 24.64% 19.27% 29.17% 28.31% 16.26% -27.16% 25.10% 22.63%
EBIT Margin		 -1.22% 36.45% 26.83% 21.26% 2.37% 34.80% 20.27% 24.50% -26.64% 26.84% 25.50%
Profit (Net Income) Margin		 1.38% 16.43% 20.86% 11.01% 8.42% 28.67% 16.66% 21.10% -18.22% 21.60% 17.66%
Tax Burden Percent		 53.74% 63.41% 68.21% 65.92% 125.80% 74.52% 71.89% 78.54% 74.15% 75.49% 69.97%
Interest Burden Percent		 -210.00% 71.07% 114.02% 78.57% 282.79% 110.54% 114.34% 109.65% 92.23% 106.60% 98.99%
Effective Tax Rate		 46.26% 36.59% 31.79% 34.08% -25.80% 25.48% 28.11% 21.46% 0.00% 24.51% 30.03%
Return on Invested Capital (ROIC)		 9.57% 57.73% 67.33% 44.82% 83.62% 73.95% 61.84% 34.39% -47.58% 58.64% 48.15%
ROIC Less NNEP Spread (ROIC-NNEP)		 9.82% 57.02% 67.07% 47.01% 89.20% 71.42% 63.39% 30.68% -47.95% 57.61% 47.43%
Return on Net Nonoperating Assets (RNNOA)		 -7.59% -43.18% -48.00% -30.46% -64.02% -51.31% -42.41% -19.05% 28.03% -39.63% -32.44%
Return on Equity (ROE)		 1.98% 14.56% 19.34% 14.37% 19.60% 22.64% 19.43% 15.34% -19.55% 19.01% 15.71%
Cash Return on Invested Capital (CROIC)		 13.65% 46.56% 49.18% 36.18% 112.39% 46.15% 14.37% -8.21% -8.99% -7.33% -24.65%
Operating Return on Assets (OROA)		 -0.82% 24.63% 18.85% 15.23% 1.61% 23.37% 14.49% 17.75% -18.91% 18.00% 17.02%
Return on Assets (ROA)		 0.93% 11.10% 14.66% 7.89% 5.72% 19.25% 11.91% 15.28% -12.93% 14.48% 11.79%
Return on Common Equity (ROCE)		 1.98% 14.56% 19.34% 14.37% 19.60% 22.64% 19.43% 15.34% -19.55% 19.01% 15.71%
Return on Equity Simple (ROE_SIMPLE)		 12.06% 0.00% 14.19% 13.52% 15.49% 0.00% 9.54% 9.52% 3.80% 0.00% 3.77%
Net Operating Profit after Tax (NOPAT)		 13 90 125 96 125 112 102 58 -80 78 61
NOPAT Margin		 2.22% 14.34% 20.15% 16.24% 24.24% 21.74% 20.35% 12.77% -19.02% 18.95% 15.84%
Net Nonoperating Expense Percent (NNEP)		 -0.25% 0.72% 0.26% -2.18% -5.58% 2.52% -1.55% 3.71% 0.37% 1.03% 0.71%
Return On Investment Capital (ROIC_SIMPLE)		 0.50% 3.48% - - - 4.66% - - - 4.16% -
Cost of Revenue to Revenue		 1.61% 1.48% 1.29% 1.56% 1.46% 1.65% 2.25% 2.54% 2.02% 1.87% 1.57%
SG&A Expenses to Revenue		 48.29% 45.85% 37.66% 41.00% 47.18% 42.49% 40.94% 48.99% 57.73% 44.39% 48.03%
R&D to Revenue		 45.98% 30.05% 31.51% 32.80% 32.10% 26.69% 28.51% 32.21% 67.41% 28.64% 27.76%
Operating Expenses to Revenue		 94.27% 75.90% 69.17% 73.81% 79.27% 69.18% 69.45% 81.20% 125.14% 73.03% 75.79%
Earnings before Interest and Taxes (EBIT)		 -7.00 229 167 126 12 179 101 111 -112 111 99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.00 230 167 126 11 179 101 112 -109 118 103
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.35 5.34 4.28 5.52 5.68 5.80 5.49 4.97 5.80 6.72 6.58
Price to Tangible Book Value (P/TBV)		 4.41 5.41 4.33 5.60 5.76 5.89 5.58 5.07 5.93 6.87 6.58
Price to Revenue (P/Rev)		 4.57 5.87 5.19 6.54 6.84 6.86 6.16 5.50 6.12 7.71 7.31
Price to Earnings (P/E)		 36.06 40.49 30.15 40.85 36.65 51.84 57.52 52.16 152.76 74.32 174.53
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 2.77% 2.47% 3.32% 2.45% 2.73% 1.93% 1.74% 1.92% 0.65% 1.35% 0.57%
Enterprise Value to Invested Capital (EV/IC)		 13.44 18.30 13.38 14.63 26.70 21.56 15.44 11.45 12.32 17.61 16.61
Enterprise Value to Revenue (EV/Rev)		 3.80 5.04 4.30 5.75 5.85 5.95 5.38 4.81 5.51 6.96 6.60
Enterprise Value to EBITDA (EV/EBITDA)		 21.32 22.23 19.93 29.20 28.75 39.80 43.17 35.79 53.54 34.65 48.67
Enterprise Value to EBIT (EV/EBIT)		 21.56 22.27 19.91 29.13 28.75 40.22 45.61 38.64 60.82 37.04 56.82
Enterprise Value to NOPAT (EV/NOPAT)		 28.27 29.65 22.50 29.92 31.75 59.55 62.08 70.95 93.20 57.62 118.43
Enterprise Value to Operating Cash Flow (EV/OCF)		 17.31 19.95 20.23 22.96 17.97 28.81 23.46 27.18 34.58 30.53 45.69
Enterprise Value to Free Cash Flow (EV/FCFF)		 120.30 43.61 29.19 43.82 17.96 43.88 113.89 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.05 0.08 0.08 0.09 0.10 0.10 0.11
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.00 0.00
Financial Leverage		 -0.77 -0.76 -0.72 -0.65 -0.72 -0.72 -0.67 -0.62 -0.58 -0.69 -0.68
Leverage Ratio		 1.45 1.45 1.35 1.36 1.43 1.43 1.41 1.41 1.46 1.44 1.44
Compound Leverage Factor		 -3.06 1.03 1.54 1.07 4.05 1.58 1.61 1.55 1.35 1.54 1.42
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 4.89% 7.08% 7.82% 8.39% 9.14% 9.02% 9.87%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 4.89% 7.08% 7.82% 8.39% 0.00% 9.02% 9.87%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.14% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 95.11% 92.92% 92.18% 91.61% 90.86% 90.98% 90.13%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.30 0.60 0.76 0.75 1.03 0.57 0.90
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 -4.84 -6.06 -6.20 -5.11 -5.89 -3.74 -5.27
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.03 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.34 0.90 1.10 1.50 1.79 0.94 2.19
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 -5.34 -9.07 -8.92 -10.13 -10.26 -6.22 -12.83
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.79 0.00 0.00
Altman Z-Score		 6.75 8.58 9.87 11.65 8.40 8.67 8.79 8.26 9.46 11.43 11.06
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.13 3.40 4.37 4.19 2.52 2.45 2.39 2.57 3.83 2.70 2.49
Quick Ratio		 2.79 3.06 3.98 3.78 2.33 2.25 2.19 2.34 3.44 2.49 2.27
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -236 -38 27 -33 405 179 31 -107 -232 -137 -129
Operating Cash Flow to CapEx		 605.61% 3,321.92% 1,950.62% 556.90% 1,163.39% 2,287.04% 2,789.47% 2,641.18% -1,472.94% 7,944.44% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -0.44 0.00 -0.67 368.47 0.00 0.00 0.00 -210.76 0.00 -107.14
Operating Cash Flow to Interest Expense		 0.00 2.77 0.00 1.30 118.45 0.00 0.00 0.00 -113.82 0.00 82.33
Operating Cash Flow Less CapEx to Interest Expense		 0.00 2.68 0.00 1.07 108.27 0.00 0.00 0.00 -121.55 0.00 83.75
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.67 0.68 0.70 0.72 0.68 0.67 0.71 0.72 0.71 0.67 0.67
Accounts Receivable Turnover		 4.99 5.13 4.99 4.95 4.71 4.78 4.96 5.02 4.88 5.56 5.97
Inventory Turnover		 0.74 0.71 0.89 0.98 1.10 1.08 1.18 1.11 0.87 0.71 0.63
Fixed Asset Turnover		 29.73 30.71 30.15 29.09 28.70 29.17 27.51 25.27 25.23 25.40 24.80
Accounts Payable Turnover		 0.08 0.07 0.07 0.10 0.10 0.10 0.10 0.10 0.09 0.08 0.08
Days Sales Outstanding (DSO)		 73.13 71.16 73.14 73.69 77.56 76.33 73.56 72.72 74.79 65.65 61.11
Days Inventory Outstanding (DIO)		 492.29 513.68 410.08 372.02 332.93 337.42 308.70 329.36 420.22 516.03 581.95
Days Payable Outstanding (DPO)		 4,561.99 4,886.71 4,923.65 3,760.80 3,644.81 3,661.03 3,756.97 3,549.03 3,984.02 4,510.58 4,690.06
Cash Conversion Cycle (CCC)		 -3,996.57 -4,301.86 -4,440.43 -3,315.10 -3,234.32 -3,247.28 -3,374.71 -3,146.95 -3,489.01 -3,928.90 -4,047.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 683 649 720 833 434 521 622 703 715 589 552
Invested Capital Turnover		 4.32 4.02 3.34 2.76 3.45 3.40 3.04 2.69 2.50 3.10 3.04
Increase / (Decrease) in Invested Capital		 248 128 98 129 -280 -67 70 165 152 215 190
Enterprise Value (EV)		 9,174 11,880 9,636 12,178 11,599 11,235 9,606 8,052 8,807 10,363 9,165
Market Capitalization		 11,027 13,820 11,634 13,855 13,551 12,946 10,986 9,201 9,777 11,482 10,158
Book Value per Share		 $25.43 $25.58 $26.93 $24.93 $23.91 $22.72 $20.50 $18.99 $17.44 $17.76 $16.15
Tangible Book Value per Share		 $25.07 $25.22 $26.58 $24.60 $23.57 $22.36 $20.14 $18.61 $17.05 $17.38 $16.15
Total Capital		 2,536 2,590 2,719 2,509 2,509 2,402 2,172 2,023 1,854 1,877 1,714
Total Debt		 0.00 0.00 0.00 0.00 123 170 170 170 170 169 169
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 170 0.00 0.00
Net Debt		 -1,853 -1,940 -1,999 -1,677 -1,952 -1,711 -1,380 -1,150 -970 -1,119 -993
Capital Expenditures (CapEx)		 11 7.30 8.10 12 11 5.40 7.60 6.80 8.50 1.80 -1.70
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 172 141 219 232 -1.70 91 33 107 164 96 90
Debt-free Net Working Capital (DFNWC)		 1,115 1,217 1,447 1,271 1,209 1,122 1,128 1,084 1,059 1,085 890
Net Working Capital (NWC)		 1,115 1,217 1,447 1,271 1,086 952 958 914 1,059 916 720
Net Nonoperating Expense (NNE)		 4.78 -13 -4.43 31 82 -36 18 -38 -3.34 -11 -7.07
Net Nonoperating Obligations (NNO)		 -1,853 -1,940 -1,999 -1,677 -1,952 -1,711 -1,380 -1,150 -970 -1,119 -993
Total Depreciation and Amortization (D&A)		 3.00 1.50 0.00 0.30 -0.90 -0.60 -0.50 1.20 2.90 7.10 4.20
Debt-free, Cash-free Net Working Capital to Revenue		 7.11% 5.98% 9.76% 10.96% -0.09% 4.81% 1.86% 6.40% 10.27% 6.44% 6.50%
Debt-free Net Working Capital to Revenue		 46.22% 51.67% 64.51% 59.98% 60.99% 59.47% 63.24% 64.78% 66.23% 72.90% 64.06%
Net Working Capital to Revenue		 46.22% 51.67% 64.51% 59.98% 54.80% 50.46% 53.72% 54.64% 66.23% 61.52% 51.88%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.08 $1.05 $1.28 $0.64 $0.43 $1.52 $0.85 $0.98 ($0.79) $0.92 $0.72
Adjusted Weighted Average Basic Shares Outstanding		 99.70M 100.40M 101.10M 100.80M 99.80M 97.70M 97.90M 97.60M 97.10M 95.80M 95.80M
Adjusted Diluted Earnings per Share		 $0.08 $1.00 $1.24 $0.63 $0.42 $1.49 $0.82 $0.95 ($0.79) $0.91 $0.69
Adjusted Weighted Average Diluted Shares Outstanding		 102.50M 103.70M 104.30M 103.90M 103.60M 101M 101.10M 100.20M 97.10M 98.90M 99M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 98.97M 99.70M 101.25M 100.98M 100.64M 99.51M 98.25M 97.65M 97.57M 96.59M 96.13M
Normalized Net Operating Profit after Tax (NOPAT)		 13 90 125 96 70 112 102 58 -80 78 61
Normalized NOPAT Margin		 2.22% 14.34% 20.15% 16.24% 13.49% 21.74% 20.35% 12.77% -19.02% 18.95% 15.84%
Pre Tax Income Margin		 2.57% 25.90% 30.59% 16.71% 6.70% 38.47% 23.18% 26.86% -24.57% 28.62% 25.24%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 2.61 0.00 2.53 11.09 0.00 0.00 0.00 -101.82 0.00 82.42
NOPAT to Interest Expense		 0.00 1.03 0.00 1.93 113.56 0.00 0.00 0.00 -72.67 0.00 51.19
EBIT Less CapEx to Interest Expense		 0.00 2.53 0.00 2.29 0.91 0.00 0.00 0.00 -109.55 0.00 83.83
NOPAT Less CapEx to Interest Expense		 0.00 0.94 0.00 1.70 103.38 0.00 0.00 0.00 -80.40 0.00 52.61
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 147.16% 87.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Neurocrine Biosciences' Financials

When does Neurocrine Biosciences's financial year end?

According to the most recent income statement we have on file, Neurocrine Biosciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Neurocrine Biosciences' net income changed over the last 9 years?

Neurocrine Biosciences' net income appears to be on an upward trend, with a most recent value of $341.30 million in 2024, falling from -$88.93 million in 2015. The previous period was $249.70 million in 2023. Check out Neurocrine Biosciences' forecast to explore projected trends and price targets.

What is Neurocrine Biosciences's operating income?
Neurocrine Biosciences's total operating income in 2024 was $570.50 million, based on the following breakdown:
  • Total Gross Profit: $2.32 billion
  • Total Operating Expenses: $1.75 billion
How has Neurocrine Biosciences revenue changed over the last 9 years?

Over the last 9 years, Neurocrine Biosciences' total revenue changed from $19.77 million in 2015 to $2.36 billion in 2024, a change of 11,814.1%.

How much debt does Neurocrine Biosciences have?

Neurocrine Biosciences' total liabilities were at $1.13 billion at the end of 2024, a 10.8% increase from 2023, and a 2,143.2% increase since 2015.

How much cash does Neurocrine Biosciences have?

In the past 9 years, Neurocrine Biosciences' cash and equivalents has ranged from $74.20 million in 2015 to $340.80 million in 2021, and is currently $233 million as of their latest financial filing in 2024.

How has Neurocrine Biosciences' book value per share changed over the last 9 years?

Over the last 9 years, Neurocrine Biosciences' book value per share changed from 4.92 in 2015 to 25.58 in 2024, a change of 419.4%.


Related Companies

This page (NASDAQ:NBIX) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored